secwatch.observer — SEC 8-K summary
======================================

Issuer:     CURIS INC (CRIS)
CIK:        0001108205
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001108205-26-000030
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curis Q4 net income $19.4M on Erivedge gain; PIPE raises $20.2M initial
-----------------------------------------------------------------------

- FY2025 net loss $7.6M ($0.58/shr) vs $43.4M ($6.88/shr) in FY2024; Q4 net income $19.4M ($1.23/shr).
- Sold Erivedge royalty assets for $2.5M upfront and liability release; recognized $27.2M non-cash gain in Q4.
- Cash $5.1M at Dec 31; Jan 2026 PIPE raised $20.2M initial, up to $20.2M more from Series B warrants; runway into H2 2027.
- Initiated Phase 2 CLL study of emavusertib + zanubrutinib; PCNSL trial: 100% ORR in BTKi-naïve (5/5) patients.
- AML triplet study: 62.5% of patients (5/8) achieved MRD conversion to undetectable after adding emavusertib to aza-ven.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1108205/000110820526000030/0001108205-26-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1108205/000110820526000030/cris-20260319.htm
  HTML page:      https://secwatch.observer/filing/0001108205-26-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer